<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_HAFS_Template skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:HAFS/Template</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar navbar-default navbar-fixed-top"><DIV class="text-center col-sm-12" id="navigation"><NAV><A href="https://2018.igem.org/Team:HAFS" id="home">Main</A><A href="https://2018.igem.org/Team:HAFS/Team">Team</A><A href="https://2018.igem.org/Team:HAFS/Business">Business</A><A href="https://2018.igem.org/Team:HAFS/Research">Research</A><A href="https://2018.igem.org/Team:HAFS/Modeling">Modeling</A><A href="https://2018.igem.org/Team:HAFS/Cooperation">Cooperation</A><A href="https://2018.igem.org/Team:HAFS/Outreach">Outreach</A><A href="https://2018.igem.org/Team:HAFS/Journal">Journal</A></NAV></DIV></DIV><DIV class="foto-grande"><DIV id="titleinsubiota"><DIV style="width:950px; margin: 0 auto"><DIV class="insubiota-text">INSUBIOTA</DIV><DIV class="insubiota-subtext">treating diabetes with genetically engineered probiotic</DIV></DIV></DIV></DIV><DIV style="width:100%; margin: 0 auto; background-color: #44558f"><DIV id="abstract">ABSTRACT</DIV><DIV style="max-width:1000px; font-size:1.5em; margin: 2% auto; line-height:1.5; text-align:justify; color: white; padding-top:2%; padding-bottom: 2%">
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria <I>Lactococcus lactis</I>, that was engineered to produce a single-chain analog insulin in human diabeticâ€™s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.

</DIV></DIV><DIV id="buttons"><DIV class="botao-link"><A href="https://2017.igem.org/Team:AQA_Unesp/Description"><DIV class="overlay" id="projectdesc"><DIV class="text">project description</DIV></DIV></A></DIV><DIV class="botao-link"><A href="https://2017.igem.org/Team:AQA_Unesp/Applied_Design"><DIV class="overlay" id="design"><DIV class="text">design</DIV></DIV></A></DIV><DIV class="botao-link"><A href="https://2017.igem.org/Team:AQA_Unesp/Results"><DIV class="overlay" id="projectdesc"><DIV class="text">results</DIV></DIV></A></DIV><DIV class="botao-link"><A href="https://2017.igem.org/Team:AQA_Unesp/HP/Silver"><DIV class="overlay" id="hpp"><DIV class="text">human practices</DIV></DIV></A></DIV><DIV class="botao-link"><A href="https://2017.igem.org/Team:AQA_Unesp/Team"><DIV class="overlay" id="team"><DIV class="text">team</DIV></DIV></A></DIV></DIV><TITLE>Team: AQA_Unesp</TITLE><DIV id="footer"><DIV id="contact" class="btm_box"><P>
			Hankuk Academy of Foreign Studies 
			International studies
			Gyeong gi, South Korea
			kyuhee0622@gmail.com</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>